About Biofidelity

Biofidelity develops molecular technologies that simplify genomic analysis for cancer diagnostics. The company's Aspyre and Enspyre technologies enable fast, reliable biomarker detection at every stage of the cancer patient journey, from early detection to treatment selection and monitoring. By removing complexity from genomic testing, Biofidelity makes precision medicine accessible to more laboratories and providers. The company addresses a critical gap. Despite advances in targeted therapies, many patients never receive genomic testing to match them with lifesaving treatments. Biofidelity's technologies work with existing equipment, delivering results in hours and bringing genomic insights directly to patients when decisions matter most.